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Abstract
Background: The human Val66Met polymorphism in brain-derived neurotrophic factor (BDNF), a key factor in neuroplasticity, 
synaptic function, and cognition, has been implicated in the pathophysiology of neuropsychiatric and neurodegenerative 
disorders. BDNF is encoded by multiple transcripts with distinct regulation and localization, but the impact of the Val66Met 
polymorphism on BDNF regulation remains unclear.
Methods: In BDNF Val66Met knock-in mice, which recapitulate the phenotypic hallmarks of individuals carrying the BDNFMet 
allele, we measured expression levels, epigenetic changes at promoters, and dendritic trafficking of distinct BDNF transcripts 
using quantitative PCR, chromatin immunoprecipitation (ChIP), and in situ hybridization.
Results: BDNF-4 and BDNF-6 transcripts were reduced in BDNFMet/Met mice, compared with BDNFVal/Val mice. ChIP for acetyl-
histone H3, a marker of active gene transcription, and trimethyl-histone-H3-Lys27 (H3K27me3), a marker of gene repression, 
showed higher H3K27me3 binding to exon 5, 6, and 8 promoters in BDNFMet/Met. The H3K27 methyltransferase enhancer of zeste 
homolog 2 (EZH2) is involved in epigenetic regulation of BDNF expression, because in neuroblastoma cells BDNF expression 
was increased both by short interference RNA for EZH2 and incubation with 3-deazaneplanocin A, an inhibitor of EZH2. In 
situ hybridization for BDNF-2, BDNF-4, and BDNF-6 after pilocarpine treatment showed that BDNF-6 transcript was virtually 
absent from distal dendrites of the CA1 and CA3 regions in BDNFMet/Met mice, while no changes were found for BDNF-2 and 
BDNF-4.
Conclusions: Impaired BDNF expression and dendritic targeting in BDNFMet/Met mice may contribute to reduced regulated 
secretion of BDNF at synapses, and may be a specific correlate of pathology in individuals carrying the Met allele.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a key factor in neuro-
plasticity, synaptic function, and cognition. Due to its pleiotropic 
effects in the brain, BDNF has been implicated in cognitive func-
tions as well as in the pathogenesis of various neuropsychiatric 
and neurodegenerative disorders (Duman and Monteggia, 2006; 
Tardito et al., 2006; Castrén et al., 2007; Martinowich et al., 2007). 
In particular, the human G196A polymorphism in the BDNF 
gene, which leads to a substitution of valine with methionine 
at codon 66 in the prodomain, has been thoroughly investigated 
for genetic associations with cognitive dysfunction, personality 
disorders, and neuropsychiatric and neurodegenerative disor-
ders (Egan et al., 2003; Hariri et al., 2003; see Fukumoto et al., 
2010; Verhagen et al., 2010 for recent meta-analyses). However, 
although a number of studies found a significant correlation of 
the Val66Met polymorphism with select disorders, others were 
unable to replicate the findings. It has been suggested that these 
conflicting results may originate from confounding factors such 
as age, gender, environmental factors, sample size, ethnicity, 
and phenotype assessment (Hong et al., 2011). In addition, it is 
likely that the complex genetic background present in human 
populations can contribute to this problem. The BDNF Val66Met 
knock-in mouse offers an opportunity to investigate the patho-
physiological consequences of the presence of the polymor-
phism in a constant and reproducible genetic background (Chen 
et al., 2006).
This knock-in mouse recapitulates the phenotypic hall-
marks of the BDNF Val66Met human polymorphism. Indeed, 
both human and mice BDNFMet allele carriers show reduced hip-
pocampal volume, cognitive deficits, increased anxiety-related 
behaviour, and impaired extinction of fear conditioning, a type 
of learning involved in phobias and posttraumatic stress disor-
der (Chen et al., 2006; Frielingsdorf et al., 2010; Soliman et al., 
2010). It has been shown that BDNFMet/Met mice display reduced 
regulated secretion of BDNF from hippocampal neurons, reduced 
dendritic arborization in the hippocampal dentate gyrus (DG), 
and reduced N-methyl-d-aspartate receptor-dependent syn-
aptic plasticity in the hippocampus (Chen et  al., 2006; Ninan 
et  al., 2010). Moreover, the binding of the BDNF transcript to 
the protein translin, required for mRNA export into dendrites, 
is disrupted by the presence of the Met mutation in the coding 
region of BDNF mRNA (Chiaruttini et al., 2009). Accordingly, we 
proposed a hypothesis for the BDNF Val66Met-associated mem-
ory deficits as a model of impaired dendritic mRNA trafficking 
(Baj et al, 2013a).
The bdnf rodent gene is composed of at least eight untrans-
lated 5’ exons and one 3’ exon encoding the protein, and dif-
ferent transcript isoforms are expressed by splicing each 
of the non-coding exons to the coding exon (Aid et  al., 2007; 
Figure 1). The complex structure of the BDNF gene allows the 
distinct BDNF transcripts to be differentially modulated at sub-
cellular locations, in specific brain regions, and in response 
to distinct stimuli (Baj et  al., 2013b; Musazzi et  al., 2014). We 
have previously shown that BDNF mRNA variants are spatially 
segregated in response to neuronal activation within three 
subcellular compartments: the soma (BDNF variants 1, 3, 5, 
7, 8, 9a), the proximal (BDNF 4)  or the distal dendrites (BDNF 
2, 6), thus behaving as a spatial code (Baj et  al., 2011, 2013b). 
Moreover, we have also shown that BDNF-6 trafficking to den-
drites is increased by physical exercise and chronic antidepres-
sant treatments (Baj et al., 2012), suggesting a role for a local 
increase of BDNF-6 mRNA at dendrites in the pro-adaptive 
effects of these two treatments. Of note, BDNF expression can 
also be altered by genetic and epigenetic regulations, includ-
ing histone posttranslational modifications (Martínez-Levy and 
Cruz-Fuentes, 2014). Accordingly, here we investigated whether 
the Val66Met mutation differentially affects the expression lev-
els, epigenetic regulation, and dendritic trafficking of the differ-
ent BDNF transcripts.
Methods
Animals
Male 3–4 month old BDNFMet/Met and BDNFVal/Val mice were used 
for all studies (Chen et al., 2006). Mice were kept at 20–22°C on 
a 12 h light/dark cycle (light on at 07:00 hours) with water and 
food available ad libitum. All animal handling and experimental 
procedures were performed in accordance with the European 
Community Council Directive 86/609/EEC and were approved 
by Italian legislation on animal experimentation (116/1992). All 
efforts were made to minimize animal distress and to reduce 
the numbers of animals used in this study.
Figure 1. Schematic representation of mouse BDNF (A) gene and (B) transcripts structure. BDNF, brain-derived neurotrophic factor; CDS, coding sequence.
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/12/pyv069/696565 by U
niversita' di Trieste user on 08 M
arch 2019
Mallei et al. | 3
RNA Isolation and Reverse Transcription
Total RNA was extracted from hippocampi of BDNFMet/Met and 
BDNFVal/Val mice, using the RNeasy Lipid Tissue Mini Kit (Qiagen) 
according to manufacturer’s instructions, and then quantified 
by absorption at A260nm, measured by UV spectrophotometry 
(NanoVue, GE Healthcare Europe GmbH). cDNA was synthesized 
from 1 μg of DNase-treated total RNA using a QuantiTect Reverse 
Transcription kit (Qiagen), following manufacturer’s directions.
Quantitative Real-Time PCR
Quantitative real time polymerase chain reaction (qPCR) analy-
sis of mRNA expression levels was performed on a 7900HT Fast 
PCR System (Applied Biosystems by Life Technologies Italia) 
by using specific primers (Table 1) and QuantiFast SYBR Green 
master mix (Qiagen). All primers were as shown previously 
(Ieraci et  al., 2015). To measure the distinct BDNF transcripts, 
we designed one specific forward primer for each 5’ exon and 
one common reverse primer in the 5’ BDNF coding sequence. To 
measure BDNF-2, BDNF-7, and total BDNF mRNA, both forward 
and reverse primers were within the respective exon region. PCR 
cycling conditions were: 10 min at 95°C, 40 cycles of 15 s at 95°C, 
and 1 min at 60°C. Data from qPCR were normalized on the mean 
of two reference genes (β-actin and glyceraldehyde-3-phosphate 
dehydrogenase). An analysis of melting curve verified the speci-
ficity of the PCR products. Relative amounts were determined 
using the comparative Cq method (Schmittgen and Livak, 2008).
Chromatin Immunoprecipitation Assay
Total hippocampi of 15 BDNFMet/Met and 15 BDNFVal/Val mice were 
used. Hippocampal tissue was cut into 1 mm3 cubes and fixed 
in 1% formaldehyde at room temperature for 15 min to cross-
link protein to DNA. Reaction was stopped by adding glycine 
(125 mM final concentration) for 5 min. Tissue was homogenized 
in sodium dodecyl sulfate (SDS) nuclei lysis buffer (50 mM Tris, 
pH 8.1, 10 mM EDTA, 1% SDS; Weinmann et al., 2001). Shearing 
of chromatin was performed with 13 cycles (20 sec on, 40 sec 
off) in a Microson sonicator (Misonix Inc.). Chromatin sonica-
tion sheared cross-linked DNA to the optimal size of 200–800 
base pairs in length. Then, 150 µl chromatin was diluted 1:10 in 
chromatin immunoprecipitation (ChIP) dilution buffer (16.7 mM 
Tris, pH 8.1, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X-100, 0.01% 
SDS). ChIPs were performed by using the MagnaChIP kit (Merck 
Millipore), following manufacturer’s instructions. Briefly, chro-
matin was immunoprecipitated at 4°C with 10 µg each of the 
following antibodies: anti-H3K27me3 (Merck Millipore, catalog 
# 07-449), anti-acetyl histone H3 (acH3, Merck Millipore, catalog 
# 06-599), or normal rabbit immunoglobulin G as control anti-
body (MagnaChIP kit, Merck Millipore). One hundredth of the 
pre-immunoprecipitated diluted chromatin was saved as input 
DNA for ChIP normalization. Immune complexes were sequen-
tially washed with low salt immune buffer, high salt buffer, 
LiCl immune complex buffer, and Tris-EDTA buffer. Protein-
DNA cross-links were reversed by heating at 62°C for 2 hours. 
After proteinase K digestion, DNA was purified by spin filter 
columns (MagnaChIP kit, Merck Millipore). To quantify histone-
associated gene promoters, immunoprecipitated DNA samples 
were subjected to qPCR on a 7900HT Fast PCR System (Applied 
Biosystems) using gene-specific primers and QuantiFast SYBR 
Green (Qiagen). The primer sequences used were either de novo 
designed using Primer Express software (Applied Biosystems) 
or previously published elsewhere (Tsankova et al., 2006). PCR 
cycling conditions were: 10 min at 95°C, 40 cycles of 15 s at 95°C, 
and 1 min at 60°C. DNA quantities were estimated from the 
quantification cycle (Cq) and then expressed as a percentage of 
corresponding input to normalize for differences in ChIP sam-
ple aliquots before immunoprecipitation. Briefly, percentage of 
input was calculated by 100 x 2(Cq-adjusted Input — Cq-enriched). Input DNA 
Table 1. List and Sequence of Primers Used in This Study
Gene Forward Reverse
Real time PCR
BDNF-1a CCTGCATCTGTTGGGGAGAC CGCCTTCATGCAACCGAAGTAT
BDNF-2a ACCTTTTCCTCCTCCTGCG TGGATGAAGTACTACCACCTCGG
BDNF-3a TGAGACTGCGCTCCACTCCC CGCCTTCATGCAACCGAAGTAT
BDNF-4a CAGAGCAGCTGCCTTGATGTTT CGCCTTCATGCAACCGAAGTAT
BDNF-6a ACAATGTGACTCCACTGCCGG CGCCTTCATGCAACCGAAGTAT
BDNF-7a ACTTACAGGTCCAAGGTCAACG GGACAGAGGGTCGGATACAG
BDNF-8a ATGACTGTGCATCCCAGGAGAAA CGCCTTCATGCAACCGAAGTAT
Total BDNFa TCGTTCCTTTCGAGTTAGCC TTGGTAAACGGCACAAAAC
EZH2a CAACCCTGTGACCATCCACG CGACATCCAGGAAAGCGGTT
ß-actina GCCAGAGCAGTAATCTCCTTCT AGTGTGACGTTGACATCCGTA
Gapdha CGTGCCGCCTGGAGAAACC TGGAAGAGTGGGAGTTGCTGTTG
ChIP
pBDNF-1b TGATCATCACTCACGACCACG CAGCCTCTCTGAGCCAGTTACG
pBDNF-2b CCGTCTTGTATTCCATCCTTTG CCCAACTCCACCACTATCCTC
pBDNF-3b GTGAGAACCTGGGGCAAATC ACGGAAAAGAGGGAGGGAAA
pBDNF-4b CTTCTGTGTGCGTGAATTTGCT AGTCCACGAGAGGGCTCCA
pBDNF-5 GCTGAAGGCGTGCGAGTATT GGCCGATATGTACTCCTGTTCTG
pBDNF-6b ACTCACACTCGCTTCCTCCT GCACTGGCTTCTCTCCATTT
pBDNF-7 GGAAGGGTGGTGAGAGAGATATAGAG GTGCCTAAGCCGGTGGTAAG
pBDNF-8 TGAAAGGAAAAAGGAGAGGCTTT AGAAAATGCCACTCCCACATAAG
aPrimer sequences as in Ieraci et al. (2015).
bPrimer sequences as in Tsankova et al. (2006).
BDNF, brain-derived neurotrophic factor; ChIP, chromatin immunoprecipitation; EZH2, enhancer of zeste homolog 2; Gapdh, glyceraldehyde-3-phosphate dehydroge-
nase; PCR, polymerase chain reaction.
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Cq was adjusted from 1% to 100% equivalent by subtracting 
6.644 Cqs or Log2 100. An analysis of melting curve verified the 
specifity of the PCR products.
Cell Cultures, 3-Deazaneplanocin A Treatment, and 
Short Interference RNA Transfection
Mouse neuroblastoma N2A cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Euroclone), containing 10% 
fetal bovine serum (Euroclone) and 1% penicillin/streptomycin 
(Euroclone) at 37oC and 5% CO2. 3-deazaneplanocin A  (DZNep) 
was purchased from Sequoia Research. DZNep was dissolved in 
distilled water and stored at -20°C.
For DZNep treatments, 2 x 105 cells were seeded in six mul-
tiwell plates 24 hours before the treatments. DZNep was added 
to cell cultures with a range of concentration (0.5; 1 and 2 μM) 
and cells were harvested 24 hours later. RNA was extracted and 
processed for qPCR analysis.
For short interference RNA (siRNA) knock-down studies, N2A 
cells were transfected with EZH2 (GeneSolution siRNA 1027416, 
Qiagen) or scramble siRNA (Negative Control siRNA 1022076, 
Qiagen) according to the optimized protocol for N2A Cells 
(Amaxa Cell Line Nucleofector Kit V, Lonza). Briefly, 1 x 105 cells 
were resuspended in 100 μl of Mouse NSC Nucleofector Solution 
containing 100 nM of siRNA and nucleofected using the Program 
T-024 on an Amaxa Nucleofector II (Lonza). Cells were harvested 
24 and 48 hours after transfection, and RNA was extracted and 
processed for qPCR analysis.
Pilocarpine Treatment
In order to measure dendritic targeting of BDNF by in situ hybridi-
zation and BDNF-2, BDNF-4, BDNF-6 and total BDNF mRNA 
expression, BDNFMet/Met and BDNFVal/Val mice were treated with pilo-
carpine (150 mg/kg, i.p., Sigma-Aldrich) dissolved in 0.9% NaCl. To 
reduce peripheral cholinergic effects, mice were pre-treated with 
methylscopolamine (1 mg/kg, i.p., Sigma-Aldrich) dissolved in 
PBS 20 min before receiving pilocarpine. For the in situ hybridiza-
tion experiment, six hours after pilocarpine administration, mice 
were anaesthetized with ketamine (100 mg/kg, i.p., Sigma-Aldrich) 
and transcardially perfused with freshly made 4% paraformalde-
hyde (PFA, in PBS pH 7.3). The brains were then removed and kept 
in 4% PFA/20% sucrose (in PBS pH 7.3) at 4°C for at least 3 days 
before sectioning in 40 µm slices using a CO2-freezing microtome 
(Leica Microsystems). For BDNF transcripts expression, the vehicle 
groups were treated in sequence with PBS (as vehicle for methyl-
scopolamine) and after 20 min with saline (as vehicle for pilocar-
pine). Six hours after either vehicle or pilocarpine administration 
mice were sacrificed, their hippocampi were collected and RNA 
was extracted and processed for qPCR analysis.
In Situ Hybridization
Five BDNFMet/Met and five BDNFVal/Val mice were used. In situ 
hybridization on free-floating 40  µm coronal brain sections 
cut at the level of the dorsal hippocampus was performed as 
described previously (Tongiorgi et  al., 1998, 2004). Specific 
probes against BDNF transcript containing BDNF-2, BDNF-4, 
or BDNF-6 were prepared from exon 2 nt 318–586 (Accession 
#NM_001270631), exon 4 nt 703–901 (Accession #X67107), or 
exon 6 nt 279–573 (Accession #S71211) cloned in pBSKS vec-
tor as previously described (Chiaruttini et  al. 2008) using the 
DIG-RNA labeling kit according to manufacturer’s instructions 
(Roche Diagnostics, Monza, Italy). Probe specificity for BDNF-2, 
BDNF-4, and BDNF-6 was previously demonstrated (Chiaruttini 
et al., 2008). Hybridization with antisense probe was performed 
at 57°C followed by high stringency washes with 0.01X sodium 
saline citrate buffer containing 0.1% Tween-20 (SSCT) at 62°C. 
In situ hybridizations on brain sections from BDNFMet/Met and 
BDNFVal/Val mice were conducted in parallel. To obtain reproduc-
ible and comparable results and avoid saturation of the reac-
tion, alkaline phosphatase development was always performed 
for 5 h at room temperature. The use of non-radioactive in situ 
hybridization with digoxigenin-labeled probes for semi-quanti-
tative evaluation of the in situ staining has been previously vali-
dated to study localization of dendritic mRNAs in vivo (Steward 
et al., 1998; Tongiorgi et al., 2004). In the present study, no saline-
injected mice were included because in our previous work the 
BDNFMet/Met and the BDNFVal/Val mice differed in dendritic targeting 
of BDNF only following pilocarpine-induced neuronal activity, 
since in the basal condition BDNF mRNA is proximally confined 
(Chiaruttini et al., 2009). In addition, we previously found no dif-
ference between saline-injected or naive animals regarding the 
distribution of total BDNF mRNA (Tongiorgi et al., 2004) or exon 
1, 2C, 4, and 6 mRNAs (Chiaruttini et al, 2008).
Statistical Analysis for ChIP and qPCR
For ChIP data, the percent input values from each data set were 
used in two-tailed unpaired t-tests to determine statistical sig-
nificance. For mRNA data, fold changes relative to the respective 
control group (∆∆Cq method) were used in two-tailed unpaired 
t-tests (when two experimental groups were analyzed), in a 
Kruskal-Wallis test followed by Dunn’ multiple comparison test 
(when more than two experimental groups were analyzed), or in 
a two-way ANOVA followed by Bonferroni’s multiple comparison 
test (when the effect of the independent factors treatment and 
genotype were considered) to determine statistical significance. 
For all analyses, a value of p < 0.05 was considered statistically 
significant. Statistical analysis of the data was carried out using 
GraphPad Prism4 (GraphPad Software).
Quantitative Image Analysis and Statistics
Non-radioactive in situ hybridization was analyzed with a Nikon 
E800 microscope (X20 and X60 magnification, Nikon) and a CCD 
camera (DXM-1200, Nikon). Images were captured with a fixed 
illumination using a procedure described previously (Tongiorgi 
et al., 2004) and analyzed with ImageJ (Schneider et al., 2012). 
Student’s t-test was used for two-sample comparisons using the 
SigmaStat software (Systat Software).
Results
Expression of Splice Variants Containing BDNF-4 
and BDNF-6 is Lower in BDNFMet/Met Mice
We assessed the levels of BDNF mRNAs containing distinct 
transcripts of non-coding exons (BDNF-1 to BDNF-8) and total 
BDNF mRNA (all transcripts containing the coding exon 9) in the 
hippocampi of BDNFVal/Val and BDNFMet/Met mice. qPCR analysis 
showed lower levels of BDNF-4 (-20.45% vs. BDNFVal/Val; p < 0.01) 
and BDNF-6 (-21.33% vs. BDNFVal/Val; p < 0.05; Figure 2) in BDNFMet/
Met mice, while no significant differences were observed for the 
other BDNF variants (Figure 2). Interestingly, levels of total BDNF 
showed a trend toward reduction, although this was not statisti-
cally significant (-14.88%; p = 0.054; Figure 2). BDNF-5 transcript 
levels were very low in both BDNFVal/Val and BDNFMet/Met mice, 
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which did not allow a reliable measurement of these mRNAs 
(not shown).
Lys27 Trimethylation of H3 Histone at Select BDNF 
Promoters is Higher in Hippocampus of BDNFMet/Met 
Mice
To understand whether epigenetic changes are involved in BDNF 
expression in mice carrying the BDNF Val66Met polymorphism, 
we investigated the regulation of chromatin architecture at dif-
ferent BDNF promoters. To this aim, we used ChIP assay com-
bined with qPCR to assess levels of acH3 and H3K27me3 at 
promoters of all non-coding BDNF transcripts (BDNF-1 to -8). 
AcH3 and H3K27me3 are known markers of transcriptional 
activation and repression, respectively (Tsankova et  al., 2006). 
AcH3 was unchanged for all BDNF promoters (Table 2). Instead, 
we found significantly higher level of H3K27me3 at BDNF-5 
(p  <  0.005), BDNF-6 (p  <  0.005), and BDNF-8 (p  <  0.05) promot-
ers in BDNFMet/Met compared to BDNFVal/Val mice (Table  2). These 
results show that reduced expression of BDNF-6 in BDNFMet/Met 
mice may be accounted for by this epigenetic change at the cor-
responding promoter. No changes were found at the BDNF-4 pro-
moter, although expression of the corresponding transcript was 
reduced in BDNFMet/Met.
EZH2 Modulates BDNF Gene Expression
H3K27 di- and trimethylation, epigenetic modifications lead-
ing to chromatin condensation and transcriptional repression, 
are mediated by the multiprotein complex Polycomb Repressive 
Complex 2 (Pasini et al., 2004; Margueron and Reinberg, 2011). 
The minimum core components necessary for the catalytic 
activity in vitro are EZH2, embryonic ectoderm development, 
and suppressor of zeste 12, with EZH2 being the actual histone 
methyltransferase in K27 trimethylation (Laugesen and Helin, 
2014). EZH2 has been involved in epigenetic reprogramming 
related to carcinogenesis (Chang and Hung, 2012; Deb et  al., 
2014). To understand whether EZH2 is able to modulate the tran-
scription of either total BDNF mRNA or BDNF-6 transcript, we 
selectively down-regulated EZH2 expression in vitro using siRNA. 
Nucleofection of EZH2 siRNA in N2A neuroblastoma cells resulted 
in about 79.10 ± 1.35% (p < 0.01) and 54.36 ± 3.37% (p < 0.05) EZH2 
mRNA reduction after 24 and 48 hours, respectively (Figure 3A). 
This reduction of EZH2 was accompanied by up-regulation of 
total BDNF of 54.10 ± 15.53% (p < 0.05) and 48.50 ± 13.18% (p < 0.01) 
after 24 and 48 hours, respectively (Figure 3A). At the same time 
Figure 2. Reduced expression of brain-derived neurotrophic factor (BDNF) transcripts in BDNFMet/Met mice. BDNF transcript expression levels were analyzed by quantita-
tive real-time PCR (qPCR). BDNFMet/Met mice showed lower levels of BDNF-4 and BDNF-6 compared to BDNFVal/Val mice. Expression levels were normalized to β-actin and 
Gapdh and expressed as a percentage relative to BDNFVal/Val mice. Data are presented as mean ± standard error of the mean (n= 6 independent biological replicates). 
Student’s t-test, *p < 0.05, **p < 0.01.
Table 2. Levels of Occupancy of acH3 and H3K27me3 at BDNF Gene 
Promoters
Gene promoter BDNFVal/Val BDNFMet/Met p-value
acH3
pBDNF-1 0.430 ± 0.0996 0.572 ± 0.1044 0.3819
pBDNF-2 0.219 ± 0.0252 0.339 ± 0.0447 0.0799
pBDNF-3 0.442 ± 0.0834 0.697 ± 0.1766 0.2616
pBDNF-4 0.491 ± 0.0478 0.493 ± 0.0938 0.9858
pBDNF-5 0.517 ± 0.0668 0.673 ± 0.1110 0.2948
pBDNF-6 0.812 ± 0.0888 1.059 ± 0.0698 0.0946
pBDNF-7 0.874 ± 0.1258 1.118 ± 0.1974 0.3561
pBDNF-8 0.099 ± 0.0249 0.1323 ± 0.0313 0.4561
H3K27me3
pBDNF-1 3.250 ± 0.3227 3.717 ± 0.3250 0.3658
pBDNF-2 3.658 ± 0.1721 4.487 ± 0.3230 0.0861
pBDNF-3 3.555 ± 0.4545 4.374 ± 0.5488 0.3143
pBDNF-4 3.196 ± 0.2194 3.300 ± 0.4021 0.8321
pBDNF-5 2.421 ± 0.0428 3.156 ± 0.079 0.0012*
pBDNF-6 3.954 ± 0.0832 4.543 ± 0.0557 0.0042*
pBDNF-7 2.992 ± 0.1374 3.657 ± 0.574 0.0851
pBDNF-8 1.645 ± 0.1478 2.331 ± 0.079 0.0150*
Data are expressed as percentage of input and presented as mean ± standard 
error of the mean. Student’s t-test. *significant difference.
BDNF, brain-derived neurotrophic factor.
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points, the increase of BDNF-6 revealed a significant difference 
only after 48 hours (12.10 ± 3.95%; p < 0.05; Figure 3A).
To further confirm the role of EZH2 in the regulation of BDNF 
gene expression, N2A cells were treated with different concentra-
tions of DZNep, which has been shown to deplete and inhibit EZH2 
(Kikuchi et al., 2012). DZNep increased the expression of both total 
BDNF and BDNF-6, with the higher response observed at 1 μM 
(total BDNF: 77.50 ± 22.79% of Veh; BDNF-6: 34.70 ± 9.22% of Veh; 
p < 0.01; Figure 3B). Therefore, the present results show that EZH2 
may modulate BDNF transcription through H3K27 methylation.
BDNF-6 Dendritic Trafficking is Impaired in 
Hippocampi of BDNFMet/Met Mice
The splice variants containing BDNF-2, BDNF-6, and, to a lesser 
extent, BDNF-4, are the main ones targeted to dendrites in hip-
pocampal neurons upon activation (Baj et al., 2011, 2013b). We 
have previously shown that trafficking of total BDNF in den-
drites upon pilocarpine treatment is abolished in the CA1 and 
CA3 hippocampal areas of BDNFMet/Met mice (Chiaruttini et  al., 
2009). Therefore, in the present study we sought to assess 
whether pilocarpine-induced dendritic targeting of these mRNA 
variants was also reduced in BDNFMet/Met mice. We employed in 
situ hybridization to measure intracellular BDNF-2, BDNF-4, and 
BDNF-6 mRNA after pilocarpine stimulation in the CA1, CA3, 
and DG areas of the hippocampi of both mouse genotypes, as 
done previously for total BDNF mRNA (Chiaruttini et al., 2009; 
Figure 4A–C). In situ hybridization experiments were carried out 
at 6 h post-pilocarpine because BDNF mRNA targeting in CA3 is 
at a maximum at this time in rodents (Tongiorgi et al., 2004) and 
CA3 is the region where the deficit in BDNF mRNA targeting is at 
a maximum in BDNFMet/Met mice (Chiaruttini et al., 2009).
Densitometric analysis of in situ labeling, to measure the 
labeling intensity at different distances from the cell body 
layer, showed no differences in BDNF-2 subcellular localiza-
tion in all three areas of the hippocampi in BDNFMet/Met mice 
with respect to BDNFVal/Val (Figure  4A). However, for BDNF-4, a 
significant reduction was found in the stratum pyramidale of 
CA1 and CA3 (Figure 4B), while no changes were found in the 
other laminas. BDNF-6 mRNA labeling was significantly reduced 
in BDNFMet/Met mice in the proximal and distal stratum radiatum 
of both CA1 and CA3 (Figure 4C). No difference in pilocarpine-
induced BDNF-6 trafficking was found in DG between the two 
genotypes. These results showed that the reduced trafficking of 
BDNF mRNA in hippocampal areas, previously found in BDNFMet/
Met mice (Chiaruttini et al., 2009), is accounted for mostly, if not 
exclusively, by BDNF-6 containing splice variant.
Pilocarpine has been shown to induce BDNF mRNA expres-
sion (Poulsen et al., 2004; Baj et al., 2013b), and since defective 
dendritic trafficking of BDNF transcripts could be due in princi-
ple to changes in either the trafficking mechanism or expres-
sion or both, we also sought to investigate whether expression 
of BDNF-2, BDNF-4, BDNF-6, and total BDNF were altered by pilo-
carpine treatment, in both genotypes. We found that pilocarpine 
Figure 3. Modulation of total brain-derived neurotrophic factor (BDNF) and BDNF-6 expression by EZH2. (A) Knockdown of EZH2 in N2A cells reduced expression of 
EZH2 (left panel). Knockdown of EZH2 induced up-regulation of total BDNF mRNA 24 and 48 hours after the nucleofection, and up-regulation of BDNF-6 after 48 hours 
(central and right panels). Expression levels were normalized to β-actin and Gapdh and results were expressed as mean ± standard error of the mean (SEM; n = 5 inde-
pendent biological replicates). *p < 0.05; **p < 0.01 compared to scramble siRNA (SCR) by Student’s t-test. (B) mRNA levels of total BDNF and BDNF-6 in N2A cells were 
increased after 24 hours of treatment with 3-deazaneplanocin A (DZNep) at 0.5, 1, and 2 μM. Expression levels were normalized to β-actin and Gapdh and results are 
expressed as mean ± SEM (n = 5–6 independent biological replicates). *p < 0.05; **p < 0.01 compared to vehicle (VEH) by Kruskal-Wallis test followed by Dunn’s multiple 
comparison test.
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increased the expression of BDNF-2, BDNF-4, and total BDNF 
similarly in both BDNFVal/Val and BDNFMet/Met mice (Figure  5A, B, 
and D), but did not affect significantly the expression of BDNF-6 
(Figure  5C). Therefore, our present and previous results com-
bined show that impaired trafficking of BDNF-6 in BDNFMet/Met 
mice is not due to reduced expression but to a selective defect 
in translocation.
Discussion
BDNF has been implicated in the pathophysiology of brain dis-
orders as well as in the action of therapeutic drugs, particularly 
antidepressants. We have previously reported that different 
BDNF transcripts code for different neuronal localization of BDNF 
(Chiaruttini et al., 2008), and that BDNF-6 is the major BDNF tran-
script targeted to dendrites upon neuronal activation (Baj et al., 
2011, 2013b). More recently, we have shown that physical exercise 
and chronic antidepressant treatments not only increase BDNF 
expression in rodent hippocampi, but also enhance targeting of 
BDNF mRNA in hippocampal dendrites, and that this increased 
trafficking is accounted for by the BDNF-6–containing splice vari-
ant (Baj et al., 2012; Ieraci et al., 2015).
The results of the present work can be summarized as fol-
lows: (1) homozygous mice carrying the human BDNF Val66Met 
Figure 4. Reduced BDNF-6 dendritic targeting in BDNFMet/Met mice after pilocarpine treatment. High-magnification pictures of the in situ hybridization and densitometric 
analysis of dendrites at progressive distances from soma for: (A) BDNF2-mRNA, (B) BDNF-4, and (C) BDNF-6 mRNAs in mouse hippocampal CA1, CA3, and dental gyrate 
(DG) regions of BDNFVal/Val and BDNFMet/Met mice. Data are expressed by the gray level of the staining; the distance is expressed in µm from the point of emergence of the 
apical dendrites from the soma (=0 µm), and the bar represents the mean ± standard error of the mean (n= 5 independent biological replicates). *p < 0.05; **p < 0.01. d.rad, 
distal radiatum; IML, inner molecular layer; lac.mol, lacunosum molecular layer; MML, medial molecular layer; OML, outer molecular layer; p.rad, proximal radiatum; 
s.gr, stratum granularis; s.luc, stratum lucidum; s.pyr, stratum pyramidale.
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polymorphism of BDNF (BDNFMet/Met) display repressive epige-
netic changes (increased H3K27me3) at BDNF promoters 5, 6, and 
8; (2) the repressive epigenetic change at the BDNF-6 promoter is 
accompanied by reduced transcription of BDNF-6; (3) neuronal 
activation–induced trafficking of BDNF-6 is also impaired in 
BDNFMet/Met mice. This impairment is not due to reduced BDNF-6 
expression, but to a defect in translocation.
In a recent genome-wide (ChIP-Seq) analysis we found differ-
ential epigenetic changes in a large number of gene promoters 
of BDNFMet/Met versus BDNFVal/Val mice (Popoli, 2012; ms. in prepa-
ration). Here we show that the presence of the human polymor-
phism also induces epigenetic changes in the BDNF gene itself. 
In particular, we have found an increase of the H3K27me3 level 
at the BDNF-6 promoter, consistent with the decrease of BDNF-6 
transcript expression. Moreover, in cell cultures we have shown 
that RNA silencing or pharmacological inhibition of EZH2, the 
methyltransferase that induces histone H3 trimethylation of 
Lys 27, increased the expression of total BDNF and BDNF-6 tran-
scripts. These results are in line with recent data showing that 
EZH2 increases the amount of H3K27me3 at BDNF promoters 
and decreases BDNF expression in endothelial cells and primary 
cortical neurons, indicating a possible common mechanism 
of BDNF regulation in different cell types (Qi et al., 2014; Mitić 
et al., 2015). The present results strongly suggest that increased 
H3K27me3 induces transcriptional repression of BDNF-6, 
although additional epigenetic changes may be involved. We 
have measured the expression of total BDNF in the hippocampi 
of BDNFMet/Met mice and found no significant changes (although 
a trend for reduction was found), in agreement with previous 
studies comparing BDNFVal/Met and BDNFMet/Met mice (Li et al., 2010; 
Yu et al., 2012). This lack of effect of the Val/Met polymorphism 
on total BDNF may suggest that the reduction in expression 
of BDNF-4 and BDNF-6 splice variants is not enough to signifi-
cantly reduce the total expression of BDNF (including all splice 
variants). However, it is noteworthy that, although total BDNF 
mRNA was found to be unchanged in BDNFMet allele carrier mice, 
the BDNF protein has been previously found to be significantly 
reduced in both BDNFVal/Met and BDNFMet/Met mice (Li et al., 2010; 
Bath et al., 2012; Yu et al., 2012).
In the present study (except for BDNF-6) we often found a 
lack of correlation between expression levels of transcripts and 
epigenetic changes at corresponding promoters. For instance, 
we found a lower expression of BDNF-4 in BDNFMet/Met mice, 
although no changes were found in H3 histone modifica-
tions. Also, differently from BDNF-4 and BDNF-6, we found no 
changes in the expression of BDNF-8 in BDNFMet/Met, although 
this promoter showed increased K27 trimethylation of associ-
ated H3 histone. However, the level of expression of a gene is 
the combinatorial result of several epigenetic changes. It is not 
surprising to find a lack of correlation between a single histone 
mark at the gene promoter and expression levels of the cor-
responding gene (see Tsankova et al., 2004). It is possible that 
additional epigenetic changes regulate transcription of BDNF-
8, explaining why in this case there is no direct correspond-
ence between increased H3K27 trimethylation and reduced 
transcription.
Figure 5. Expression of BDNF-6 is not altered by pilocarpine. (A) Pilocarpine treatment increased BDNF-2 expression levels in the hippocampi of BDNFVal/Val and BDNFMet/
Met mice [two-way ANOVA, treatment effect: F(1,19) = 13,83, p = 0.0015; genotype effect: F(1,19) = 0,02023, p = 0,8884; interaction: F(1,19) = 1,289e-005, p = 0,9972]. (B) Pilocarpine 
treatment increased BDNF-4 expression levels in the hippocampi of BDNFVal/Val and BDNFMet/Met mice [two-way ANOVA, treatment effect: F(1,18) = 11.31, p = 0,0035; genotype 
effect: F(1,18) = 0,0538, p = 0,8192; interaction: F(1,18) = 0,00645, p = 0,9369]. An additional post hoc analysis with Student’s t-test confirmed lower BDNF-4 levels in BDNF
Met/
Met vs. BDNFVal/Val mice (p = 0.0325). (C) BDNF-6 expression levels were analyzed by quantitative real-time PCR (qPCR) in the hippocampi of BDNFVal/Val and BDNFMet/Met 
mice. Treatment with pilocarpine did not modify BDNF-6 levels [two-way ANOVA, treatment effect: F(1,19) = 0,4259, p = 0,5218; genotype effect: F(1,19) = 1.870, p = 0,1874; 
interaction: F(1,19) = 0,1794, p = 0,6767]. An additional post hoc analysis with Student’s t-test confirmed lower BDNF-6 levels in BDNF
Met/Met vs. BDNFVal/Val mice (p = 0.0309). 
(D) Pilocarpine treatment increased total brain-derived neurotrophic factor (BDNF) expression levels in the hippocampi of BDNFVal/Val and BDNFMet/Met mice [two-way 
ANOVA, treatment effect: F(1,18) = 11.93, p = 0,0028; genotype effect: F(1,18) = 0,1005, p = 0,7548; interaction: F(1,18) = 0,1471, p = 0,7059]. Expression levels were normalized to 
β-actin and Gapdh and expressed as a percentage relative to BDNFVal/Val control mice. Data are presented as mean ± standard error of the mean (n= 5–7 independent 
biological replicates). Two-way ANOVA of vehicle (Veh) groups vs. pilocarpine treated (Pilo) groups followed by Bonferroni’s multiple comparison test (*p < 0.05 compared 
to respective vehicle group) or Student’s t-test (#p < 0.05 compared to BDNFVal/Val vehicle).
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We have previously shown that dendritic targeting of total 
BDNF is defective in BDNFMet/Met mice (Chiaruttini et  al., 2009). 
Interestingly, as shown here, BDNFMet/Met mice display a selective 
impairment of BDNF-6 targeting to dendrites in the CA1 and 
CA3 hippocampal areas. Combined with our previous results, 
showing that increased BDNF dendritic trafficking induced by 
physical exercise and chronic antidepressants is accounted for 
by BDNF-6 (Baj et al., 2012), the present results suggest a cru-
cial role for BDNF-6 in mediating some effects of the neurotro-
phin at synaptic locations. It can be envisaged that defective 
dendritic targeting of BDNF mRNA in BDNFMet/Met mice is mainly 
due to changes in BDNF-6. Of note, we found that at 6 h post-
pilocarpine treatment, BDNF-2 mRNA was not detectable in hip-
pocampal laminas containing dendrites either in BDNFVal/Val or in 
BDNFMet/Met mice. This finding suggests that BDNF-2 mRNA tar-
geting may have a different time-course with respect to BDNF-6.
The present findings add to the significance of the BDNF 
Val66Met knock-in mice as an interesting model that recapitu-
lates several aspects of neuropsychiatric pathology (Frielingsdorf 
et  al., 2010). Reduced expression and dendritic targeting of 
BDNF-6 could be a causal factor for reduced regulated release 
of BDNF at synapses, found in this knock-in mouse (Chen et al., 
2006).
It is not known how the presence of the BDNF polymorphism 
may affect epigenetic regulation of BDNF transcription. At pre-
sent, a likely explanation is that BDNF and other neurotrophins 
are capable of regulating their own transcription (Mallei et al., 
2004; Wibrand et al. 2006; Yasuda et al., 2007). This regulation is 
selective for different BDNF transcripts, as we have shown pre-
viously (Musazzi et  al., 2014). Reduced availability of BDNF at 
synapses may in turn contribute to reduced dendritic develop-
ment and hippocampal volume, which are recognized features 
of BDNF Val66Met knock-in mice. This could be a distinct feature 
of pathology not only in mice, but also in humans carrying the 
BDNF Val66Met polymorphism that display reduced hippocam-
pal volume (Frodl et al., 2007). In addition, because dendritic tar-
geting of BDNF-6 is involved in the antidepressant mechanism 
(Baj et al., 2012), the impairment of this mechanism in BDNFMet/
Met mice could be a reason for the lack of response to selective 
serotonin reuptake inhibitors in these mice (Chen et al., 2006; 
Bath et al., 2012).
It has been proposed that dysfunction in the glutamate sys-
tem, including altered glutamate release/transmission, clear-
ance, and metabolism, has a central role in neuropsychiatric 
pathophysiology (Sanacora et  al., 2012). BDNF has a crucial 
role in the regulation of transmission and plasticity at gluta-
mate synapses, and BDNFMet/Met mice have been shown to have 
impaired synaptic plasticity in the hippocampus (Ninan et  al., 
2010). Further studies are warranted to investigate the effects 
of BDNF-6 overexpression or silencing on synaptic function and 
behavior, as well as on the response to stress. It will also be inter-
esting to assess the behavioral and cellular/molecular effects of 
chronic antidepressants or physical exercise in Val66Met knock-
in mice, considering the specific influence exerted by these envi-
ronmental factors on BDNF-6 expression and targeting (Baj et al., 
2012) and its ability to modify the number of dendritic branches 
in the distal portion of the dendritic arbor (Baj et al., 2011).
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